Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
- 18 June 2015
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 11 (8), 1193-1201
- https://doi.org/10.1517/17425255.2015.1058779
Abstract
A medical need remains for a once-daily insulin with 24-h basal coverage in all patients. We characterize the steady-state (SS) pharmacokinetic/pharmacodynamic properties of insulin degludec (IDeg) versus insulin glargine (IGlar). In this controlled, single-center study, 66 type 1 diabetes patients were randomized to two 8-day periods of once-daily IDeg or IGlar at 0.4, 0.6 or 0.8 U/kg. At SS, subjects underwent a 42-h euglycemic glucose clamp (5.5 mmol/l; 100 mg/dl). Glucose infusion rate (GIR), distribution of GIR and half-life were assessed. Mean 24-h GIR profiles were flatter and more stable for all doses of IDeg versus IGlar. The evenly distributed glucose-lowering effect of IDeg was confirmed by the AUCGIR across one dosing interval, as each of the four 6-h intervals across one dosing interval contributed ∼ 25% of the AUCGIR,τ,SS. IGlar was most effective during the first 12 - 18 h after dosing. At SS, the half-life was 25.4 (IDeg) versus 12.1 h (IGlar). No safety concerns were identified for IDeg or IGlar. IDeg has a longer half-life (> 25 h) than IGlar. Exposure and glucose-lowering effects are more stable and evenly distributed across one dosing interval for IDeg versus IGlar (Clinical trials.gov identifier: NCT01114542).This publication has 17 references indexed in Scilit:
- Insulin Stacking Versus Therapeutic Accumulation: Understanding the DifferencesEndocrine Practice, 2014
- Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine SocietyDiabetes Care, 2013
- The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time DailyDiabetes Care, 2013
- Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetesDiabetes, Obesity and Metabolism, 2012
- Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetesDiabetes, Obesity and Metabolism, 2012
- Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal InsulinPharmaceutical Research, 2012
- Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studiesDiabetes, Obesity and Metabolism, 2007
- Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetesDiabetes, Obesity and Metabolism, 2006
- Twice‐daily compared with once‐daily insulin glargine in people with Type 1 diabetes using meal‐time insulin aspartDiabetic Medicine, 2006
- To: Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1988–1995Diabetologia, 2006